(September 30, 2016, 9:24 AM EDT) -- WASHINGTON, D.C. — Mylan Pharmaceuticals Inc. and Mylan Inc. (collectively, Mylan) ask the U.S. Supreme Court in a Sept. 19 petition whether the filing of an abbreviated new drug application (ANDA)...
Mylan Asks High Court If ANDA Subjects Filers To Specific Personal Jurisdiction
To view the full article, register now.
Try for FREE for fourteen days
Already a subscriber? Click here to login